Biotechnology
Compare Stocks
2 / 10Stock Comparison
OMER vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
OMER vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.03B | $1712.35T |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-121M | $-168M |
| Total Debt | $207M | $22M |
| Cash & Equiv. | $3M | $194M |
OMER vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Omeros Corporation (OMER) | 100 | 95.0 | -5.0% |
| DBV Technologies S.… (DBVT) | 100 | 40.7 | -59.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OMER vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
OMER carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.79
- EPS growth -43.6%
- 16.6% 10Y total return vs DBVT's -87.0%
DBVT is the clearest fit if your priority is quality.
- 0.3% margin vs OMER's -4.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 11.4% revenue growth vs DBVT's -100.0% | |
| Quality / Margins | 0.3% margin vs OMER's -4.8% | |
| Stability / Safety | Beta 0.79 vs DBVT's 1.26 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +130.6% vs DBVT's +110.4% | |
| Efficiency (ROA) | -53.9% ROA vs DBVT's -89.0% |
OMER vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
OMER and DBVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$127M | -$112M |
| Net IncomeAfter-tax profit | -$121M | -$168M |
| Free Cash FlowCash after capex | -$105M | -$151M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +16.1% | +91.5% |
Valuation Metrics
OMER leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $1.0B | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $1.2B | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -5.42x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | — | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
Evenly matched — OMER and DBVT each lead in 3 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs OMER's 3/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | -130.2% |
| ROA (TTM)Return on assets | -53.9% | -89.0% |
| ROICReturn on invested capital | -72.4% | — |
| ROCEReturn on capital employed | -64.8% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | — | 0.13x |
| Net DebtTotal debt minus cash | $204M | -$172M |
| Cash & Equiv.Liquid assets | $3M | $194M |
| Total DebtShort + long-term debt | $207M | $22M |
| Interest CoverageEBIT ÷ Interest expense | -5.80x | -189.82x |
Total Returns (Dividends Reinvested)
OMER leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in OMER five years ago would be worth $8,248 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, OMER leads with a +130.6% total return vs DBVT's +110.4%. The 3-year compound annual growth rate (CAGR) favors OMER at 43.1% vs DBVT's 6.2% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -10.6% | +4.9% |
| 1-Year ReturnPast 12 months | +130.6% | +110.4% |
| 3-Year ReturnCumulative with dividends | +192.8% | +19.7% |
| 5-Year ReturnCumulative with dividends | -17.5% | -69.1% |
| 10-Year ReturnCumulative with dividends | +16.6% | -87.0% |
| CAGR (3Y)Annualised 3-year return | +43.1% | +6.2% |
Risk & Volatility
OMER leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
OMER is the less volatile stock with a 0.79 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. OMER currently trades 82.9% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.70x | 1.26x |
| 52-Week HighHighest price in past year | $17.65 | $26.18 |
| 52-Week LowLowest price in past year | $2.95 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +82.9% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 70.5 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 1.0M | 252K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates OMER as "Buy" and DBVT as "Buy". Consensus price targets imply 173.2% upside for OMER (target: $40) vs 131.8% for DBVT (target: $46).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $40.00 | $46.33 |
| # AnalystsCovering analysts | 19 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.2% | 0.0% |
OMER leads in 3 of 6 categories (Valuation Metrics, Total Returns). DBVT leads in 1 (Income & Cash Flow). 1 tied.
OMER vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is OMER or DBVT a better buy right now?
Analysts rate Omeros Corporation (OMER) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OMER or DBVT?
Over the past 5 years, Omeros Corporation (OMER) delivered a total return of -17.
5%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: OMER returned +12. 5% versus DBVT's -87. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OMER or DBVT?
By beta (market sensitivity over 5 years), Omeros Corporation (OMER) is the lower-risk stock at 0.
70β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 81% more volatile than OMER relative to the S&P 500.
04Which is growing faster — OMER or DBVT?
On earnings-per-share growth, the picture is similar: Omeros Corporation grew EPS -43.
6% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — OMER or DBVT?
Omeros Corporation (OMER) is the more profitable company, earning 0.
0% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OMER leads at 0. 0% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — OMER leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — OMER or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is OMER or DBVT better for a retirement portfolio?
For long-horizon retirement investors, Omeros Corporation (OMER) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
70)). Both have compounded well over 10 years (OMER: +12. 5%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between OMER and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.